JPMorgan Raises Rigel Pharma (RIGL) to 'Overweight' Ahead of Fostamatinib Phase 3 ITP Data
Tweet Send to a Friend
(Updated - April 22, 2016 9:50 AM EDT)JPMorgan upgraded Rigel Pharmaceuticals (NASDAQ: RIGL) from Neutral to Overweight with a price ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
